Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer

被引：0
|
作者：
Lin, Jessica Jiyeong
Tan, Daniel Shao-Weng
Kummar, Shivaani
Patel, Jyoti D.
Cermignani, Luciano
Dai, Ming-Shen
Lassen, Ulrik Niels
Leyvraz, Serge
Liu, Yongmei
Moreno, Victor
Rosen, Lee S.
Saada-Bouzid, Esma
Solomon, Benjamin Maurice
Xu, Rui-Hua
Yachnin, Jeffrey
Norenberg, Ricarda
Burcoveanu, Domnita-Ileana
Mussi, Chiara E.
Shen, Lin
Drilon, Alexander E.
机构：
[1] Massachusetts Gen Hosp, Dept Med, Boston, MA USA
[2] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[3] Duke NUS Med Sch, Singapore, Singapore
[4] Oregon Hlth & Sci Univ, Portland, OR USA
[5] Northwestern Univ, Chicago, IL USA
[6] Hosp Aleman, Buenos Aires, Argentina
[7] Tri Serv Gen Hosp, Taipei, Taiwan
[8] Rigshosp, Dept Oncol, Copenhagen, Denmark
[9] Charite Univ Med Berlin, Berlin, Germany
[10] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China
[11] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China
[12] START MADRID FJD, Hosp Fdn Jimenez Diaz, Madrid, Spain
[13] UCLA, Div Hematol Oncol, Santa Monica, CA USA
[14] Univ Cote Dazur, Ctr Antoine Lacassagne, Nice, France
[15] Avera Canc Inst, Sioux Falls, SD USA
[16] Sun Yat Sen Univ, State Key Lab, Canc Ctr, Guangzhou, Peoples R China
[17] Karolinska Univ Hosp, Stockholm, Sweden
[18] Chrestos Concept GmbH & Co KG, Essen, Germany
[19] Bayer Healthcare Pharmaceut Inc, Basel, Switzerland
[20] Bayer SpA, Milan, Italy
[21] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China
[22] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9056
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
    Rieke, D. T.
    Lin, Iyeong J.
    Tan, D. S.
    Kummar, S.
    Patel, J. D.
    Cermignani, L.
    Dai, M. -S.
    Lassen, U. N.
    Leyvraz, S.
    Liu, Y.
    Moreno, V.
    Rosen, L.
    Saada-Bouzid, E.
    Solomon, B.
    Xu, R. -H.
    Yachnin, J.
    Norenberg, R.
    Burcoveanu, D. -I.
    Mussi, C. E.
    Shen, L.
    Drilon, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 9 - 10
  • [2] Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
    Drilon, A.
    Moreno, V.
    Patel, J.
    Lassen, U. N.
    Solomon, B.
    Rosen, L.
    Leyvraz, S.
    Tan, D. S. W.
    Reeves, J. A.
    Dima, L.
    Brega, N.
    Kummar, S.
    Farago, A. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S834 - S834
  • [3] Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer
    Tan, D.
    Farago, A.
    Kummar, S.
    Moreno, V.
    Patel, J.
    Lassen, U.
    Solomon, B.
    Rosen, L.
    Leyvraz, S.
    Reeves, J.
    Brega, N.
    Dima, L.
    Childs, B.
    Drilon, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S176 - S176
  • [4] Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer
    Drilon, A.
    Moreno, V.
    Patel, J.
    Lassen, U.
    Solomon, B.
    Rosen, L.
    Leyvraz, S.
    Tan, D. S. W.
    Reeves, J. A.
    Dima, L.
    Brega, N.
    Kummar, S.
    Farago, A. F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S30 - S31
  • [5] Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion Cancer
    Rieke, D. T.
    Hong, D. S.
    Drilon, A.
    Tan, D. S.
    Lin, J.
    Kummar, S.
    McDermott, R.
    Berlin, J.
    Italiano, A.
    Lassen, U. N.
    Leyvraz, S.
    Tahara, M.
    Norenberg, R.
    Burcoveanu, D. -I.
    Brega, N.
    Shen, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 142 - 143
  • [6] Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
    Hong, David S.
    Drilon, Alexander E.
    Tan, Daniel Shao-Weng
    Lin, Jessica Jiyeong
    Kummar, Shivaani
    McDermott, Raymond S.
    Berlin, Jordan
    Italiano, Antoine
    Lassen, Ulrik Niels
    Leyvraz, Serge
    Tahara, Makoto
    Norenberg, Ricarda
    Burcoveanu, Domnita-Ileana
    Brega, Nicoletta
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.
    Drilon, Alexander E.
    Hong, David S.
    Van Tilburg, Cornelis Martinus
    Doz, Francois
    Tan, Daniel S. W.
    Kummar, Shivaani
    Lin, Jessica Jiyeong
    McDermott, Raymond S.
    Zwaan, C. Michel
    Norenberg, Ricarda
    Fellous, Marc Mardoche
    Brega, Nicoletta
    Xu, Rui-Hua
    Laetsch, Theodore Willis
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
    Drilon, Alexander E.
    Lin, Jessica Jiyeong
    Kummar, Shivaani
    Tan, Daniel Shao-Weng
    Patel, Jyoti D.
    Lassen, Ulrik Niels
    Leyvraz, Serge
    Moreno, Victor
    Rosen, Lee S.
    Solomon, Benjamin Maurice
    Yachnin, Jeffrey
    Liu, Yongmei
    Dai, Ming-Shen
    Norenberg, Ricarda
    Fellous, Marc Mardoche
    Mussi, Chiara Erminia
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An expanded dataset
    Garralda, E.
    Hong, D.
    Xu, R.
    Deeken, J.
    Italiano, A.
    Liu, T.
    Ferrandiz, A.
    Patel, J.
    Lee, D.
    Chung, H.
    Kinoshita, I.
    Berlin, J.
    Andre, T.
    Oh, D.
    Leyvraz, S.
    Miguel, M.
    Liu, Y.
    Norenberg, R.
    Fellous, M.
    Mussi, C.
    Drilon, A.
    Shen, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S370 - S370
  • [10] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis
    Andre, T.
    Hong, D.
    Deeken, J.
    Italiano, A.
    Liu, T.
    Burcoveanu, D.
    Norenberg, R.
    Mussi, C.
    Xu, R.
    Drilon, A.
    Shen, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S12 - S13
12345